185 related articles for article (PubMed ID: 36546465)
1. A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30
Pinter A; Gold LS; Reich A; Green LJ; Praestegaard M; Selmer J; Armstrong AW; Danø A; Dhawan S; Galván J; Stallknecht SE; Trebbien P; Augustin M
J Eur Acad Dermatol Venereol; 2023 Jan; 37 Suppl 1():14-19. PubMed ID: 36546465
[TBL] [Abstract][Full Text] [Related]
2. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis.
Pinter A; Green LJ; Selmer J; Praestegaard M; Gold LS; Augustin M;
J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):228-236. PubMed ID: 34628687
[TBL] [Abstract][Full Text] [Related]
3. Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene/ Betamethasone Dipropionate Cream Versus Suspension/Gel.
Armstrong A; Pinter A; Selmer J; Præstegaard M; Reich A; Koo J
J Drugs Dermatol; 2022 Mar; 21(3):242-248. PubMed ID: 35254765
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, quality of life, and treatment satisfaction: an indirect comparison of calcipotriol/betamethasone dipropionate cream versus foam for treatment of psoriasis.
Reich A; Selmer J; Galván J; Trebbien P; Pi-Blanque A; Danø A; Stallknecht SE; Bewley A
Curr Med Res Opin; 2022 Sep; 38(9):1521-1529. PubMed ID: 35575759
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Pinter A; Reich A; Arenberger P; Gold LS; Armstrong A; Iversen L; Praestegaard M; Augustin M
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2327-2335. PubMed ID: 37432045
[TBL] [Abstract][Full Text] [Related]
6. An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis.
Bewley A; Barker E; Baker H; Green W; Avey B; Pi-Blanque A; Galván J; Trebbien P; Praestegaard M
J Dermatolog Treat; 2022 Dec; 33(8):3191-3198. PubMed ID: 36036596
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream.
Stein Gold L; Green LJ; Dhawan S; Vestbjerg B; Praestegaard M; Selmer J
J Drugs Dermatol; 2021 Apr; 20(4):420-425. PubMed ID: 33852251
[TBL] [Abstract][Full Text] [Related]
8. Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review.
Torres T; Galván J; Crutchley N; Praestegaard M; Iversen L; Gisondi P; Carrascosa JM; Halioua B; Bewley A; Pinter A
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2153-2169. PubMed ID: 37740858
[TBL] [Abstract][Full Text] [Related]
9. Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey.
López Estebaranz JL; Kurzen H; Galván J
J Dermatolog Treat; 2024 Dec; 35(1):2357618. PubMed ID: 38797809
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis.
Kontzias CL; Curcio A; Gorodokin B; Tissera KA; Feldman SR; Bhatia N; Callender VD; Kircik L
J Drugs Dermatol; 2023 Jul; 22(7):668-672. PubMed ID: 37410050
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies.
Stein Gold L; Pinter A; Armstrong A; Augustin M; Arenberger P; Bhatia N; Praestegaard M; Iversen L; Reich A
Dermatol Ther (Heidelb); 2023 Sep; 13(9):2031-2044. PubMed ID: 37490268
[TBL] [Abstract][Full Text] [Related]
13. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Jalili A; Lebwohl M; Stein Gold L; Andersen SB; Jensen KL; Pink AE; Segaert S; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):709-717. PubMed ID: 30520168
[TBL] [Abstract][Full Text] [Related]
14. A novel calcipotriol and betamethasone dipropionate (CAL/BDP) PAD-cream demonstrates greater improvements in daily activities and personal relationships than CAL/BDP gel/TS: A post-hoc analysis of DLQI outcomes from two phase 3 placebo-controlled randomized clinical trials in mild-to-moderate psoriasis.
Halioua B; Caillet G; Taieb C; Bewley A; Snel-Prentø A; Praestegaard M; Armstrong A; Pinter A
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):e326-e328. PubMed ID: 37907283
[No Abstract] [Full Text] [Related]
15. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
[TBL] [Abstract][Full Text] [Related]
16. Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence.
Takahashi H; Katayama H; Uwajima Y; Koda M; Sasaki H; Tanito K; Hagiwara M; Matsuo K; Nakagawa H
J Dermatol; 2020 Nov; 47(11):1249-1256. PubMed ID: 32734661
[TBL] [Abstract][Full Text] [Related]
17. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
[TBL] [Abstract][Full Text] [Related]
18. INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment.
Reddy R; Khan S; Kircik L; Armstrong AW
J Drugs Dermatol; 2023 Aug; 22(8):SF381621s5-SF381621s10. PubMed ID: 37556526
[TBL] [Abstract][Full Text] [Related]
19. Engaging psoriasis patients in adherence and outcomes to topical treatments: A summary from the Symposium 'Tailoring topical psoriasis treatments to patients' needs and expectations' of the 30
Bewley A; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2023 Jan; 37 Suppl 1():9-13. PubMed ID: 36546463
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
